In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View

Alexion Pharmaceuticals Inc.

http://www.alexion.com

Latest From Alexion Pharmaceuticals Inc.

Take Five: Ipsen Bags Rights To Day One Brain Cancer Drug

Bookmark
  • News
By Kevin Grogan

The Paris-based group has inked five external deals already this year, this time paying $111m to get access internationally to Day One Biopharmaceuticals' Ojemda for refractory pediatric low-grade glioma.

Deals Cancer

Medtechs Are Fully Engaged In Climate Change: ‘They Have No Choice’

Bookmark
  • Analysis
By Ashley Yeo

The E in ESG: SUDs, reuse, disposables, refurbishing, reprocessed devices? Multiple panelists at the 2024 MedTech Forum addressed the role medtech manufacturers should have in the climate change challenge.

Sustainability Market Intelligence

Digital Health Roundup: Brain Talk On Seizures, Alzheimer's, Stress, Anxiety; Medtronic's OR Report; Health Care AI; UK Guidances

Bookmark
  • Analysis
By Marion Webb, Natasha Barrow, Brian Bossetta and Hannah Daniel

In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb highlights AI discussions at the HLTH Europe conference and an interview with Motif Neurotech's CEO Jacob Robinson. Elizabeth Orr discusses DeepWell DTx's newly launched VR game for treating stress-related hypertension and anxiety. Natasha Barrow provides an overview of Digital Mental Health Technologies regulation in the UK and Brian Bossetta reports ‘the good and bad’ from Medtronic's report on digital technologies' use in the operating room. 

Digital Health Roundup Digital Health

Grünenthal Bolsters US Portfolio With Buyout Of Valinor

Bookmark
  • Analysis
By Joseph Haas

Deal snapshot: The German pain-management specialist is acquiring Valinor to gain additional geographic rights to the gastrointestinal drug Movantik and add to its US product portfolio.

M & A Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
  • Biotechnology
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Alexion Pharma K.K. (formerly Legend K.K. or Legend Pharma Co., Ltd.) (Japan)
    • AstraZeneca PLC
    • AstraZeneca Rare Disease
    • Enobia Pharma Corp.
    • LogicBio Therapeutics, Inc.
    • Portola Pharmaceuticals, Inc. (PTLA)
    • Synageva BioPharma Corp.
    • Syntimmune, Inc.
    • Taligen Therapeutics, Inc.
    • Wilson Therapeutics AB
UsernamePublicRestriction

Register

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By